Open access
Open access
Powered by Google Translator Translator

Neurology

Perspective | Will unpredictable side effects dim the promise of new Alzheimer’s drugs?

8 Aug, 2023 | 13:30h | UTC

Will unpredictable side effects dim the promise of new Alzheimer’s drugs? – Science (a few articles per month are free)

Related:

RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns

RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns

 


Review | Treatment of pediatric convulsive status epilepticus

4 Aug, 2023 | 11:42h | UTC

Treatment of pediatric convulsive status epilepticus – Frontiers in Neurology

 


RCT | Recombinant human prourokinase demonstrates noninferiority to alteplase in acute ischemic stroke treatment

3 Aug, 2023 | 13:46h | UTC

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

 


Study | Frequent soccer heading linked to cognitive impairment risk in retired players

3 Aug, 2023 | 13:12h | UTC

Heading Frequency and Risk of Cognitive Impairment in Retired Male Professional Soccer Players – JAMA Network Open

Invited Commentary: Heading Frequency and Risk of Cognitive Impairment in Retired Male Professional Soccer Players – JAMA Network Open

Related:

Cohort study | Professional soccer players are at increased risk of Alzheimer’s disease and other dementias

Dementia risk in former professional footballers is related to player position and career length.

Study: Neurodegenerative Disease Mortality Increased Among Former Professional Soccer Players

 

Commentary on Twitter

 


Review | Diagnosing delirium in perioperative and intensive care medicine

3 Aug, 2023 | 13:09h | UTC

Diagnosing delirium in perioperative and intensive care medicine – Current Opinion in Anesthesiology

 


RCT | Multiple sclerosis disease-modifying therapy continuation versus discontinuation in older individuals

2 Aug, 2023 | 14:00h | UTC

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial – The Lancet Neurology (link to abstract – $ for full-text)

Commentaries:

Study investigates risk when discontinuing therapy for MS patients over 55 – CU Anschutz Medical Campus

Discontinuing Multiple Sclerosis Therapies at Age 55 or Older – NEJM Journal Watch

 


RCT | Atogepant outperforms placebo in reducing migraines over 12 weeks

2 Aug, 2023 | 13:56h | UTC

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


Cohort Study | Depression at any life stage linked to increased dementia incidence

2 Aug, 2023 | 13:49h | UTC

Association of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort – JAMA Neurology (link to abstract – $ for full-text)

Commentary: Depression Over Adulthood May Increase Risk of Dementia – Psychiatric News Alert

 


Review | First-line immunosuppression in neuromuscular diseases

1 Aug, 2023 | 14:09h | UTC

First-line immunosuppression in neuromuscular diseases – Practical Neurology

 


Review | Multiple system atrophy

1 Aug, 2023 | 14:08h | UTC

Multiple system atrophy – Practical Neurology

 


Review | Clinical assessment of parietal lobe function

1 Aug, 2023 | 14:03h | UTC

Clinical assessment of parietal lobe function – Practical Neurology

 


Review | Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology

31 Jul, 2023 | 14:07h | UTC

Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology – Neurology

News Release: AAN issues guidance on new treatments for early Alzheimer’s disease – American Academy of Neurology

 


Phase 2 Trial | Oral orexin receptor 2 agonist shows promise in narcolepsy type 1, but raises hepatotoxic concerns

28 Jul, 2023 | 14:09h | UTC

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT – 2ry Analysis | Elevated intracranial bleeding risk with low-dose aspirin in older adults

27 Jul, 2023 | 13:09h | UTC

Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

News Release: Low dose aspirin won’t help some older adults trying to avoid a stroke: study – Monash University

Commentary: Daily aspirin doesn’t prevent strokes in older, healthy people after all – The Conversation

Original Study: Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Related Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.

Related Randomized Trials:

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

Related Meta-Analysis:

Meta-Analysis: Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events

Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups – BMC Medicine

Related Opinions:

Aspirin for Primary Prevention: Is This the End of the Road?

Evidence evolving on aspirin as prevention – ACP Internist

#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders

 


Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness

26 Jul, 2023 | 13:28h | UTC

Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness – The Lancet Respiratory Medicine

 


RCT | Vitamin D supplementation shows no cognitive benefit in mild cognitive impairment intervention

25 Jul, 2023 | 14:00h | UTC

Effects of Exercise Alone or Combined With Cognitive Training and Vitamin D Supplementation to Improve Cognition in Adults With Mild Cognitive Impairment: A Randomized Clinical Trial – JAMA Network Open

Commentary: Exercise and Cognitive Training Slow Thinking Declines. Vitamin D? Not So Much – HealthDay

Related:

RCT | No statistically significant impact of vitamin D on major cardiovascular events

2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults

RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

 


Global, regional, and national burden of meningitis and its etiologies, 1990–2019

25 Jul, 2023 | 13:55h | UTC

Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Neurology

 

Commentary on Twitter

 


Systematic Review | Existing research on post-stroke depression interventions lacks conclusive results

25 Jul, 2023 | 13:37h | UTC

Pharmacological, non‐invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke – Cochrane Library

Summary: Pharmacological, non-invasive brain stimulation and psychological interventions for treating depression after stroke – Cochrane Library

 


RCT | Hearing intervention fails to impact 3-year cognitive decline in older adults

20 Jul, 2023 | 11:09h | UTC

Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Prospective Study | Intelligence likely remains intact after pediatric concussion

20 Jul, 2023 | 11:06h | UTC

IQ After Pediatric Concussion – Pediatrics (free for a limited period)

Commentaries:

IQ After Pediatric Concussion: Clinical Considerations – Pediatrics

No Evidence Seen for Differences in IQ After Pediatric Concussion – HealthDay

Concussions do not affect IQ in children, study finds – News Medical

 


RCT | Ischemic stroke patients benefit from Panax notoginseng saponins therapy

20 Jul, 2023 | 10:57h | UTC

Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China: A Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

Commentary: Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke? – News Medical

 


Review | Painful diabetic peripheral neuropathy

20 Jul, 2023 | 10:53h | UTC

Painful Diabetic Peripheral Neuropathy: Practical Guidance and Challenges for Clinical Management – Diabetes, Metabolic Syndrome and Obesity

 


RCT | Solanezumab fails to slow cognitive decline in preclinical Alzheimer’s disease

19 Jul, 2023 | 14:26h | UTC

Trial of Solanezumab in Preclinical Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Related:

RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns

RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns

 

Commentary on Twitter

 


RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns

18 Jul, 2023 | 13:51h | UTC

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial – JAMA (free for a limited period)

Editorials:

Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed? – JAMA (free for a limited period)

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease – JAMA (free for a limited period)

Ushering in a New Era of Alzheimer Disease Therapy – JAMA (free for a limited period)

See also: Visual Abstract

Commentary: Expert reaction to results from Eli Lilly on its anti-amyloid drug donanemab – Science Media Centre

Related: RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns.

 


Nationwide Cohort Study | Adolescent hypertension linked with increased stroke risk in young adulthood

18 Jul, 2023 | 13:49h | UTC

Adolescent Hypertension Is Associated With Stroke in Young Adulthood: A Nationwide Cohort of 1.9 Million Adolescents – Stroke

Commentary: The Relationship Between Adolescent Hypertension and Stroke Risk After Age 40 Years – Neurology Advisor

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.